JHVEPhoto Shares of Amgen (NASDAQ:AMGN) surged after the company reported first quarter results, but the gain was largely driven by management comments related to the phase 2 trial of the long-acting obesity candidate maridebart cafraglutide (which was previously called AMG133), or MariTide as it is conveniently called. No results were reported, but the comments about…
magnetcreative/E+ via Getty Images Eli Lilly (LLY) has been a phenomenal stock to own over the past couple of years. In early 2022, it was trading for about $230 per share, but today it trades for nearly $800. This huge run is largely due to the success of its obesity drug, “Zepbound”. Eli Lilly shares…
bymuratdeniz/E+ via Getty Images Pemvidutide’s Pounds and Problems: Altimmune’s Balancing Act Since December, Altimmune’s (NASDAQ:ALT) stock has nearly tripled since revealing obesity data (MOMENTUM) in late November for their GLP-1/glucagon agonist, pemvidutide (subcutaneous weekly). Altimmune is not the first to study GLP-1/glucagon agonism. Several drugs are currently in development, including Merck’s (MRK) efinopegdutide, Eli Lilly’s…